Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaTreatment OutcomeHistocompatibilityHistocompatibility TestingGraft SurvivalRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticMyelodysplastic SyndromesStem CellsImmunosuppressive AgentsVidarabineRemission InductionCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicLiver TransplantationSiblingsCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTime FactorsTransplantation ImmunologySurvival RateHematopoiesisSurvival AnalysisCytomegalovirus InfectionsAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalSevere Combined ImmunodeficiencyMice, Inbred C57BLFollow-Up StudiesOpportunistic InfectionsMultiple MyelomaCystitisFlow CytometryMinor Histocompatibility AntigensLeukemic InfiltrationHematopoietic Stem Cell MobilizationLeukemia, MyeloidAntigens, CD34ImmunosuppressionKidney TransplantationNeoplasm, ResidualAntilymphocyte SerumSyndromeSalvage TherapyLymphoproliferative DisordersBone and BonesGraft RejectionCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusFatal OutcomePrognosisRisk FactorsImmunocompromised HostBlood Group IncompatibilityBronchiolitis ObliteransCyclosporineBone Marrow PurgingCytarabineCell TransplantationColony-Forming Units AssayMelphalanMycosesMesenchymal Stem Cell TransplantationPrimary MyelofibrosisLymphoma, Non-HodgkinRadiation ChimeraCell LineageGanciclovir